Introduction
Immunoglobulin (Ig)A nephropathy (IgAN), characterized by the deposition predominantly of IgA in the mesangium, is the most prevalent primary glomerulonephritis worldwide. Although IgAN was considered previously a benign disease, researchers have recognized that up to 40% of IgAN patients will progress to end-stage renal disease (ESRD) within 20 years of diagnosis [1] . Various approaches intended to prevent IgAN progression have been attempted, but the best therapy for the disease remains incompletely established. According to the current Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline [2] , reninangiotensin system (RAS) inhibitors are recommended for controlling blood pressure and are partly effective to achieve proteinuria <1 g/day. Glucocorticoids are recommended for IgAN patients with persistent proteinuria. However, the broad severe side-effects profile of steroids limits their use in patients, and evidence is still lacking regarding the efficacy of combined immunosuppressive therapy in patients with IgAN. There are no disease-targeted treatments for IgAN. The development of such treatments depends upon an evolving understanding of the pathogenesis of the disease.
Accumulating evidence suggests that complement activation plays a prominent role in the pathogenesis of IgAN [3, 4] . Activation of the complement system results in cleavage of C3 and C5, as well as the generation of terminal effective products that have diverse biological functions, including induction of inflammatory responses by the small fragments (C3a, C5a), direct killing of pathogens by the membrane attack complex (MAC) C5b-9 and opsonization of pathogens through C3b and its metabolites. C3a and C5a have gained increasing attention for their role in inducing overwhelming inflammation. By signalling through their G protein-coupled receptors (C3aR and C5aR or C5L2), C3a and C5a induce cytokine and chemokine release, neutrophil and macrophage chemoattraction and macrophage activation [5] . Previous studies have reported increased plasma concentrations of C3a [6, 7] , as well as glomerular over-expression of C5aR, in IgAN patients [8] , findings indicative of the existence of a relationship between C3a and C5a and IgAN. Our previous study demonstrated that increased generation of C3a and C5a, as well as enhanced expression of their receptors, may be crucial for the progression of IgAN [9] .
Therefore, inhibition of C3a, C5a and their receptors may be a promising therapy for the disease. Recently, two patients with rapidly progressive IgAN that were treated with an anti-C5 antibody (eculizumab) experienced renal functional improvement or stabilization and reduced proteinuria [10, 11] . These results highlight the need for further research exploring the potential usefulness of targeting C3a, C5a and their receptors as a therapy for the disease. The purpose of this study is to define the effect of C3aR/C5aR inhibition on IgA1-stimulating HMCs in vitro and to investigate whether C3a/C5a receptor deficiency can reduce the extent and severity of renal injury further in an IgAN mice model and thus provide a foundation for the development of a novel targeted therapy for IgAN in the future. An experimental model of IgAN induced by Sendai virus was employed here because it mimicked the clinical character of IgAN that a mucosal infection always plays in evolution of the disease.
Materials and methods

HMCs culture
A well-characterized human mesangial cell line was generously provided to us by Shanghai Medical College, Fudan University. The cells were cultivated in RPMI-1640 (GIBCO, Grand Island, NY, USA) medium supplemented with 10% fetal bovine serum (GIBCO) and 1% penicillin-streptomycin at 378C in a humidified atmosphere of 5% CO 2 in air.
Human mesangial cell (HMC) proliferation assay by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method in vitro Cell proliferation was determined using the MTT assay. HMCs were grown to confluence, harvested by trypsinization and seeded into a 96-well plate at a density of 10 4 cells/well. IgA1 isolated from pooled human serum was purchased from Sigma-Aldrich (St Louis, MO, USA). Both the C3aR antagonist (catalogue no. 559410, CAS 1140525-25-2) and the C5aR antagonist (catalogue no. 234415, CAS 405098-33-1) were purchased from Calbiochem (San Diego, CA, USA). The cells were treated with blank medium or medium containing 100 lg/ml IgA, 100 lg/ml IgA 1 100 lM C3aR antagonist or 100 lg/ml IgA 1 100 lM C5aR antagonist for 48 h at 378C. There were six parallel wells in every group and negative control group. After treatment the cells were washed with serum-free medium, and 20 ll of 5 mg/ml MTT solution (Sigma, St Louis, MO, USA) was added to each well. After incubation for 4 h at 37 C, the MTT-containing medium was removed by aspiration. The blue formazan product generated was dissolved by the addition of 200 ll of 100% dimethyl sulphoxide (DMSO) to each well. The absorbance of solubilised blue formazan was recorded at 490 nm by a microplate reader. Cell proliferation percentages were calculated using the following equation: [mean optical density (OD) of treated cells/ mean OD of control cells] 3 100.
Detection of receptor and cytokine mRNA expression by reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Total RNA was extracted using Trizol reagent (Invitrogen, Karlsruhe, Germany). Gel electrophoresis was used to determine RNA integrity. For real-time quantitative PCR, 5 ll of DNase-treated total RNA was reverse-transcribed using an AMV First Strand cDNA synthesis kit. RT-qPCR was performed using an ABI StepOnePlus TM real-time fluorescence quantitative PCR instrument and ABI SybrGreen PCR Master Mix. PCR was set up in 96-well microplates containing 10 ll of Master Mix, 2 ll of cDNA and 10 pmol of each 3 0 and 5 0 primer pair for either the target genes or the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene (internal reference), yielding a 20-ll reaction volume. PCR amplification was carried out for 3 min at 958C and for 20 s at 608C, followed 40 cycles of 20 s at 728C. Gene expression was expressed as 2 -DDCt , where Ct is the cycle threshold, DCt 5 Ct (target gene) -Ct (GAPDH) and DDCt 5 DCt (IgAN) -DCt (normal control). The primer sequences are shown in Table 1 .
Detection of receptor and cytokine protein expression by Western blotting
The cells were washed with ice-cold phosphate-buffered saline (PBS) and gently resuspended in ice-cold RIPA buffer with freshly added 1% protease inhibitor cocktail before being incubated on ice for 10 min. The cell lysates were centrifuged at 9700 3 g for 10 min at 4 C, and the supernatant was prepared as a protein extract. The protein concentration was determined using a bicinchoninic acid assay kit (Dingguo Bioscience, Beijing, China). Samples containing 60 lg of total protein were separated on a 10% sodium dodecyl sulphate polyacrylamide gel and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skimmed milk solution in 0Á1% Tris-buffered saline Tween-20 (Dingguo Bioscience) for 1 h. The membranes were incubated subsequently with either mouse antihuman C3aR monoclonal antibodies (1 : 500 dilution; AbD Serotec, Oxford, UK), mouse anti-human C5aR monoclonal antibodies (1 : 500 dilution; AbD Serotec), rabbit anti-human interleukin (IL)-6 monoclonal antibodies (1 : 800 dilution; Abcam, Cambridge, UK), rabbit antihuman MCP-1 polyclonal antibodies (1:1000 dilution, Abcam) or rabbit anti-human GAPDH polyclonal antibodies (1 : 800 dilution; Good Here Bioscience, Hangzhou, China) overnight at 4 C with gentle shaking. After washing, horseradish peroxidase (HRP)-conjugated secondary antibodies (1 : 2000 dilution; Jackson Immuno-Research, West Grove, PA, USA) were added to the mixture, which was incubated for 2 h at 378C. Antibody binding was detected using an electrochemiluminescence (ECL) detection kit (Thermo Scientific, Rockford, IL, USA) to produce a chemiluminescence signal, which was captured on X-ray film. Band intensities were quantified from scanned membrane images using Image J software (National Institutes of Health, Bethesda, MD, USA).
Animals
Homozygous C3aR
-/-and C5aR -/-mice on aBALB/c genetic background were purchased from Jackson Laboratory (stock no.: 005712 and 006845, respectively; Jackson Labs, Bar Harbor, ME, USA). Wild-type (WT) BALB/c mice were purchased from the Laboratory Animal Centre of Zhengzhou University. Female mice (6-8 weeks old) were used for model preparation. The animal procedures were performed in accordance with the institution's guidelines for the care and use of laboratory animals and were approved by the ethics committee of our university.
Sendai virus preparation
Sendai virus Strain 52 was obtained from the Wuhan Institute of Virology, Chinese Academy of Sciences. Expansion of infectious suspensions of viral stock was conducted in chicken embryos. A total of 0Á2 ml of Sendai virus concentrate was diluted in 1 ml of virus suspension with PBS, and the virus dilution was injected into live fertile eggs (0Á15 ml per egg) at a point opposite the embryo. The eggs were placed into an incubator at 378C. Live eggs were selected by 'candling' after 24 h, and these eggs were then incubated further at 378C for 28 h. After 52 h of incubation, the eggs were chilled to 48C and incubated overnight. Allantoic fluid was withdrawn from the eggs slowly and then centrifuged at 1500 3 g at 48C for 25 min. The supernatant was divided into 1-ml working stock aliquots and stored in liquid nitrogen for use. The virus titre for each mouse was calculated as the geometric mean of the number of plaques formed in a haemagglutination plaque assay, multiplied by the dilution factor.
Induction and analysis of the mouse IgAN model
The mouse IgAN model was generated by Sendai virus infection, as described previously [12, 13] . Three groups of each mouse strain (C3aR
-/-and WT, seven mice per group) were immunized intranasally with 25 ll of a suspension containing inactivated Sendai virus weekly for 14 weeks. The initial dose of inactivated virus was 2Á5 3 10 4 for the first and second times to reduce morbidity and mortality from viral pneumonia. Subsequently, the amount of inactivated virus administered to the immunized mice increased gradually to 2Á5 3 10 5 at the third week, 2Á4 3 10 6 at the fourth week and 1Á92 3 10 8 from weeks 5 to 14. On weeks 6 and 14, the immunized mice were challenged intravenously with 0Á2 ml of suspension containing 6Á25 3 10 8 of virus via the tail vein. Seven WT mice that were not exposed to any virus served as negative controls and received an equivalent volume of sterile PBS on the same days and by the same route as the immunized groups. 
C3aR 5 C3a receptor; C5aR 5 C5a receptor; TNF 5 tumour necrosis factor; TGF 5 transforming growth factor; IL 5 interleukin; MCP-1 5 monocyte chemotactic protein 1; GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase.
Uninfected and Sendai virus-infected experimental mice were housed in microisolator cages in separate rooms, isolated from each other and from the other animals, and were fed ad libitum with sterile food and water.
Twenty-four-h urine samples were collected from each mouse in metabolic cages before immunization and at the end of the 14th week for proteinuria analysis. Urinary protein was measured with a pyrogallol red-molybdate complex in an automated analyser (CS-400B; Dirui, Changchun, China). Blood samples (0Á2-0Á3 ml per mouse) were obtained by puncturing the retrobulbar veins with capillary glass pipettes 1 day before the experiment. Blood samples (0Á8-1Á2 ml per mouse) were taken again from the retrobulbar veins after killing. Renal function was assessed by measuring serum creatinine (SCr) and blood urea nitrogen (BUN) concentrations on an automatic biochemical analyser (CS400; Roche, Rotkreuz, Switzerland). Serum C3 level determinations were performed using enzyme-linked immunosorbent assay (ELISA) kits (Abcam), according to the manufacturer's instructions.
Histological analysis
The mice were killed at the end of week 14. The mice were anaesthetized with 10% chloral hydrate. Laparotomy was performed and the kidneys were harvested. One-fourth of one kidney was fixed in 4% paraformaldehyde (pH 7Á4) and embedded in paraffin. The paraffin sections (3 lm) were stained in haematoxylin and eosin (H&E), periodic acid-Schiff (PAS) and Masson's trichrome. Evaluation of renal histological changes was performed blindly by two pathologists using a light microscope. A sample of fresh renal cortex (approximately 1/8 of the kidney) was optimal cutting temperatureembedded, snap-frozen and sectioned at 4 lm. For direct immunofluorescence microscopy, slides were incubated with either fluorescein isothiocyanate-conjugated goat anti-mouse IgA polyclonal antibodies (1 : 10 dilution; AbD Serotec) or rat anti-mouse C3 monoclonal antibodies (1 : 50 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 30 min at 378C. After washing, slides were observed with a fluorescence microscope. Staining intensity was expressed as follows: negative, invisible; weak, ambiguous under a low-power lens and apparent under a high-power lens; moderate, apparent under a low-power lens and clear under a high-power lens; intense, clear under a low-power lens and bright under a high-power lens; and very intense, dazzling under a high-power lens. The remaining kidney tissues were stored in liquid nitrogen for use.
RNA extraction from kidney tissues
Approximately 50 mg of thawed kidney tissue samples was homogenized in 1 ml of Trizol reagent (Invitrogen). The homogenized samples were then incubated for 10 min at room temperature to permit complete dissociation of RNA; 0Á2 ml of chloroform was added to the homogenized samples, which were shaken vigorously and incubated again at room temperature for 5 min. The samples were centrifuged at 9700 3 g at 48C for 20 min, and the aqueous phase was transferred to a new tube. 0Á5 ml of isopropyl alcohol was added to the aqueous phase to precipitate the RNA. Samples were mixed and incubated at room temperature for 10 min and then centrifuged at 9700 3 g at 48C for 15 min. The supernatant was removed and the RNA pellet was washed with 1 ml of 70% ethanol. The sample was centrifuged again at 9700 3 g at 48C for 3 min. After discarding the supernatant the pellet was air-dried, after which it was resuspended in 100 ll of RNase-free water. The RNA samples were treated with DNase, and then purified on RNeasy Mini columns (Qiagen, Valencia, CA, USA) and washed out with 50 ll of RNase-free water. Renal tumour necrosis factor (TNF)-a, transforming growth factor (TGF)-b, IL-1b, IL-6 and monocyte chemotactic protein 1 (MCP-1) mRNA expression levels were detected by RT-qPCR, as mentioned above.
Detection of renal cytokine expression by immunohistochemistry
The paraffin-embedded sections were cut, deparaffinized and hydrated by soaking in 100% xylene and sequential descending ethanol concentrations, followed by microwave heating in citrate buffer (pH 6Á0). Next, the sections were incubated in 0Á3% H 2 O 2 in PBS to block endogenous peroxidase activity. After washing, the sections were incubated with either anti-TNF-a polyclonal antibodies (1 : 200 dilution; Abcam), anti-TGF-b polyclonal antibodies (1 : 200 dilution; Abcam), anti-IL-1b polyclonal antibodies (1 : 400 dilution; Bioss, Beijing, China), anti-IL-6 polyclonal antibodies (1 : 400 dilution; Bioss) or anti-MCP-1 polyclonal antibodies (1 : 300 dilution; Abcam) overnight at 48C in a moist chamber. Biotinylated secondary antibodies (1 : 100 dilution; Zhongshan Golden Bridge, Beijing, China) were incubated for 20 min at 378C, and avidin-biotin-peroxidase complexes (1 : 20 dilution; Zhongshan Golden Bridge) were applied. Colour development was obtained by treatment with diaminobenzidine. Finally, the sections were counterstained with haematoxylin, dehydrated, sealed and observed by light microscopy. The positively stained cells in 10 fields of two stained kidney sections from each animal were quantified at a magnification of 3200 and expressed as numbers of cells per field.
Statistical analysis
Data are presented as the mean 6 standard deviation (s.d.). Significant differences between multiple groups were analysed by one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc test. Paired-sample t-tests were used to compare proteinuria and renal function before and after 14 weeks of Sendai virus immunization, and the immunofluorescence results for IgA and C3 were compared by the Mann-Whitney U-test. A P-value less than 0Á05 was considered statistically significant. All analyses were performed 
Results
IgA stimulation increased C3aR/C5aR expression in HMCs
RT-qPCR and Western blot analysis demonstrated increased C3aR and C5aR expression in HMCs incubated with 100 lg/ml IgA for 48 h, findings demonstrative of C3aR and C5aR activation in HMCs after IgA stimulation. Elevated C3aR or C5aR expression could be inhibited by C3aR or C5aR antagonism, respectively.
C3aR/C5aR antagonism inhibited HMC proliferation after IgA stimulation in vitro
Enhanced cell proliferation, as measured by MTT assay, was observed when HMCs were incubated with 100 lg/ml IgA for 48 h (cell viability: 168Á1 6 5Á0% versus 100Á0 6 6Á9% in the IgA-stimulated and blank control groups, respectively, P < 0Á001; Fig. 1a) . We subsequently investigated the potential effects of C3aR or C5aR antagonism on modulating IgAstimulated HMC proliferation. Administration of a C3aR or C5aR antagonist at a concentration of 100 lM inhibited HMC proliferation significantly after IgA stimulation (cell viability in the IgA-stimulated 1 C3aR antagonist group: 113Á8 6 9Á3%, cell viability in the IgA-stimulated 1 C5aR antagonist group: 121Á5 6 4Á6%, P < 0Á001 versus the IgAstimulated group; Fig. 1a ). There was no significant difference in the HMC proliferation down-regulation elicited by C3aR versus C5aR antagonism (P 5 0Á363).
C3aR/C5aR antagonism reduced IL-6 and MCP-1 up-regulation after IgA stimulation in vitro Elevated IL-6 and MCP-1 mRNA expression was observed when the HMCs were incubated with IgA-containing and MCP-1 protein expression. *P < 0Á05, **P < 0Á01, ***P < 0Á001 versus negative control. medium, and these elevations were reduced significantly by the addition of a C3aR or C5aR antagonist (Fig. 1b) . Correspondingly, IL-6 and MCP-1 protein synthesis was upregulated in all the IgA-stimulated groups compared with the negative control group (Fig. 1c,d ). IL-6 and MCP-1 expression up-regulation was reduced by C3aR or C5aR antagonism (Fig. 1c,d ), paralleling our findings regarding gene expression. With respect to IL-6 and MCP-1 gene expression and protein synthesis levels, no differences between C3aR antagonism and C5aR antagonism were noted (P > 0Á05).
Sendai virus infection induced IgAN in mice
Proteinuria was considered evidence of glomerular dysfunction and clinical nephritis. After 14 weeks of immunization proteinuria was exhibited by immunized WT mice, whose daily proteinuria increased from 1Á38 6 0Á35 mg to 2Á63 6 0Á39 mg (P 5 0Á001). Proteinuria levels in immunized WT mice were significantly greater than those in non-immunized controls at the end of week 14 (2Á63 6 0Á39 mg/24 h versus 1Á12 6 0Á25 mg/24 h, P < 0Á001). IgA and C3 deposition was not observed in the normal glomeruli of non-immunized mouse renal specimens. Granularpositive staining of IgA accompanied by C3 deposition was noted in the mesangium of glomeruli of immunized WT mice at week 14, a finding demonstrative of the diagnosis of IgAN after immunization.
C3aR/C5aR deficiency reduced proteinuria in IgAN mice
Proteinuria in C3aR
-/-and C5aR -/-IgAN mice was reduced significantly compared to that in WT mice with IgAN (1Á89 6 0Á46 g/24 h in C3aR -/-IgAN mice versus 2Á63 6 0Á39 g/24 h in WT IgAN mice, P 5 0Á005; 1Á59 6 0Á31 g/24 h in C5aR -/-IgAN mice versus 2Á63 6 0Á39 g/24 h in WT IgAN mice, P < 0Á001; Table 2 ). No significant difference in serum creatinine or BUN was detected among the various groups, including the control group (P > 0Á05). Serum C3 levels in C3aR -/-and C5aR -/-IgAN mice were significantly lower than those in WT IgAN mice (P 5 0Á017 and 0Á049, respectively).
C3aR/C5aR deficiency markedly attenuated histological injury
No IgA and C3 staining was noted in normal renal tissues.
Immunofluorescence revealed IgA deposits accompanied by C3 deposits in the mesangium of the glomeruli from Sendai virus-immunized mice at week 14. Less IgA deposition was observed in the mesangium of C3aR -/-and C5aR -/-IgAN mice than in the mesangium of WT IgAN mice (P 5 0Á011 and 0Á007, respectively; Fig. 2a , Table 3 ). C3 staining intensity in the mesangium was also reduced in C3aR -/-and C5aR Table 3 ). Light micrographs of the kidney tissues from immunized WT mice showed mesangial matrix expansion and hypercellularity, as well as some interstitial infiltration. Mesangial matrix expansion and hypercellularity were also reduced in C3aR -/-and C5aR -/-IgAN mice (Fig. 2c ).
C3aR/C5aR deficiency reduced cytokine and chemokine up-regulation in IgAN mice
No positive staining of cytokines and chemokines, including TNF-a, TGF-b, IL-1b, IL-6 and MCP-1, was noted in the normal glomeruli from the renal specimens of the negative control group. Deposition of these cytokines and chemokines was scarcely observed in the tubular epithelial cells of normal kidney tissues. For WT IgAN mouse renal specimens, IL-1b and MCP-1 were deposited mainly in tubular epithelial cells and occasionally in mesangial cells, while IL-6, TNF-a and TGF-b were deposited mainly in mesangial cells and tubular epithelial cells. The deposits of all these factors in C3aR -/-and C5aR -/-IgAN mice had similar distribution patterns ( Fig. 3 and Supporting information, Fig. S1 ). However, the number of TNF-a, TGF-b, IL-1b, IL-6 or MCP-1 positive cells was significantly lower in C3aR -/-and C5aR -/-IgAN mice than in IgAN mice ( Fig.   3 and Supporting information, Fig. S1 , Table 4 ). In addition, the number of IL-1b-or IL-6-positive cells was significantly lower in C3aR -/-IgAN mice than in C5aR -/-IgAN mice (P 5 0Á034 and 0Á015, respectively), while the number of MCP-1 positive cells was marginally lower in the former group than in the latter (P 5 0Á057). The numbers of TNFa-and TGF-b-positive cells were comparable between C3aR -/-and C5aR -/-IgAN mice. The RT-qPCR results showed that renal TNF-a, TGF-b, IL-1b, IL-6 and MCP-1 mRNA expression levels were elevated in all three immunized groups compared with the negative control group. The gene expression levels of these cytokines and chemokines were reduced significantly in C3aR -/-and C5aR -/-IgAN mice compared with WT IgAN mice (Fig. 4) . In particular, renal IL-1b, IL-6 and MCP-1 mRNA were expressed in lower amounts in C3aR -/-IgAN mice than in C5aR -/-IgAN mice (Fig. 4) .
Discussion
C3a and C5a are the major inflammatory effectors of complement activation and exert proinflammatory effects by 7  0  0  0  0  7  0  0  0  0  Immunized WT mice  0  0  3  3  1  1  0  3  3  0  Immunized C3aR  -/-mice  1  2  4  0  0  3  2  2  0  0  Immunized C5aR  -/-mice  1  3  3  0  0  3  2  2  0  0 Glomerular IgA and C3 deposition was measured by immunofluorescence staining. The numbers in the table represent the numbers of mice with the corresponding immunofluorescence staining intensities. After being immunized with the Sendai virus to induce IgA nephropathy, C3aR
-/-and C5aR -/-mice exhibited significantly reduced IgA and C3 deposition in the kidney compared to wild-type (WT) mice (P < 0Á05).
binding to their respective receptors. In the current study, we found that C3aR/C5aR antagonists inhibited HMC proliferation induced by IgA1 stimulation in vitro. Furthermore, we demonstrated that C3aR or C5aR deficiency can also inhibit renal cytokine and chemokine expression in vivo. Moreover, the current study is the first report to demonstrate that C3aR or C5aR deficiency can reduce proteinuria successfully and attenuate renal histological injury in the IgAN mice model. Our results serve as definitive evidence indicating that C3a, C5a and their receptors play prominent roles in the pathogenesis of IgAN and represent a foundation on which potential therapies targeting and blocking C3aR/C5aR to treat IgAN in the future can be based. Our data showed that C3aR/C5aR deficiency reduced urinary protein levels markedly in IgAN mice. However, no significant improvements in renal function were observed.
Administration of an anti-C5 antibody to a patient with rapidly progressive IgAN led to clinical improvements; namely, glomerular filtration rate stabilization and reduced proteinuria [10] . Another case report also demonstrated a significant immediate improvement in renal function after anti-C5 antibody administration to patients with crescentic IgAN [11] . The diverse effects of complement inhibition on renal function may be attributed to differences in renal injury severity between the mouse model and the reported cases. The mouse model used in this study is a model of proliferative IgAN. No significant elevations in serum creatinine were noted after model preparation. However, both reported cases presented with more severe IgAN with renal insufficiency. Further research may be carried out on heminephrectomied hyper IgA (HIGA) mice, a potential model for progressive glomerulosclerosis of human IgAN [14] , to clarify whether C3a/C5a blockage is useful for maintaining renal function. In addition, the diverse effects of complement inhibition on renal function may result from the different impacts of various effectors on the kidney. Anti-C5 antibodies can block MAC and C5a production, but not C3a production. In our previous study, C3a and C5a showed clearer correlations with proteinuria than renal function. In contrast, MAC was reported to be correlated more clearly with renal function than proteinuria [15] . These results indicate that the major effectors of complement activation, C3a, C5a and MAC, may play slightly different roles in the progression of the disease. Further research is necessary to clarify their precise roles in the pathogenesis of IgAN. It is worth noting that IgA deposition was decreased markedly in the kidney of C3aR -/-and C5aR -/-mice compared to WT mice in the present IgAN model. However, conventional wisdom suggests that IgA deposits in the mesangium initially and then induces complement activation to generate terminal effectors, including C3a and C5a. It thus seems confusing that IgA deposition was affected by C3aR/C5aR deficiency. This result suggested strongly that C3a/C5a activation took place earlier than IgA deposition in the kidney. Several studies have described increased plasma levels of C3 breakdown products in patients with IgAN [7, 16, 17] , indicating that complement activation can take place on circulating IgA1-containing immune complexes before their deposition in the mesangium. Moreover, according to our data, C3a and C5a activation seems to prompt IgA deposition rather than occur as a sequential consequence of IgA deposition. The influence of C3a and C5a on B cell responses has been known for many years, but the notion that C3a and C5a also contribute to the activation, expansion and survival of T cells and antigenpresenting cells (APCs) has only recently gained impetus [18] . C3a, C5a and their receptors are supposed to modify APC antigen presentation and participate in the formation of pathogenic immune complexes composed of galactosedeficient IgA1 and anti-glycan antibodies [4] . If this is the case, the above-mentioned decrease in IgA deposition in the kidney of C3aR/C5aR-deficient mice was reasonable. Future work will need to address the impact of anaphylatoxins on the production of antiglycan antibodies and the formation of pathogenic immune complexes.
In theory, inhibiting C3aR or C5aR should not affect the complement activation step, as C3a and C5a are downstream effectors. However, we observed that C3 depletion . Data are expressed as the mean 6 standard deviation. *P < 0Á05, **P < 0Á01, ***P < 0Á001 versus negative control.
in the circulation, as the result of systemic complement activation, was rescued partly by C3aR-or C5aR-deficiency in the IgAN mice model. C3aR or C5aR deficiency also decreased renal C3 deposition in the present IgAN mice model, indicating that local complement activation in the kidney was restrained. This suggested that complement activation may be regulated by a feedback loop. It has been reported that decreased joint C3 deposition occurred in C3aR -/-and C5aR -/-mice compared to WT mice in a collagen antibody-induced arthritis model [19] , findings supporting the possible existence of a positive feedback pathway regulating C3 activation that is promoted by C3a and C5a through their receptors. Our study found that a lack of C3aR or C5aR reduced renal expression of the proinflammatory factors TNF-a, TGF-b, IL-1b, IL-6 and MCP-1 in vivo and may thus contribute to the amelioration of proteinuria and histological injury in C3a/C5a-deficient IgAN mice. In addition, IL-1b, IL-6 and MCP-1 expression levels were decreased significantly in C3aR-deficient IgAN mice compared to C5aR-deficient IgAN mice. A recent study also found that C3aR-deficient dendritic cells produced less IL-1b [20] , results that corresponded with ours. IL-1b, IL-6 and MCP-1 are generated by monocytes/macrophages and T cells. It was reported C3aR deficiency rather than C5aR deficiency led to significantly reduced monocyte/macrophage and T cell recruitment in the tubulointerstitium [21] , providing a possible explanation for the above-mentioned decreases in renal IL-1b, IL-6 and MCP-1 expression in C3aR-deficient IgAN mice.
Interestingly, C3aR deficiency, but not C5aR deficiency, inhibited the renal expression of some cytokines and chemokines significantly (such as IL-1b, IL-6 and MCP-1) in vivo; however, C3aR and C5aR deficiency seemed to have similar protective effects on proteinuria and histological damage. Cytokine and chemokine release induced by C3a or C5a precedes renal damage and clinical presentations; thus, we suppose that discrepancies in cytokine and chemokine expression could be observed in earlier stages of the disease. Distinct roles for C3a and C5a were demonstrated in complement-induced tubulointerstitial injury [21] . In the indicated previous study, C3aR deficiency led to significantly reduced renal leucocyte infiltration and less severe tubulointerstitial inflammation and fibrosis and ultimately preserved renal function. In contrast, the absence of C5aR was inconsequential. The histological changes in our mouse model were very slight, without obvious tubulointerstitial injury, so the diverse roles of C3a and C5a cannot be documented. However, the differences in the renal expression levels of the above-mentioned cytokines and chemokines provided us with some clues that C3a/C3aR signalling may play a more important role in IgAN progression. Blocking C3aR may be a feasible treatment for severe IgAN.
Mesangial cells were found to secrete proinflammatory factors and proliferate after polymeric IgA stimulation in our study. This pathogenic course could be blocked by C3aR or C5aR deficiency, verifying the protective effects of C3aR/C5aR deficiency on mesangial cells in vitro. Remarkably, the reductions in IL-6 and MCP-1 secretion caused by C3aR or C5aR blockage were not significantly different in cultured mesangial cells, while C3aR deficiency demonstrated a stronger potential to inhibit IL-6 and MCP-1 renal expression than C5aR deficiency in vivo, perhaps because of the loss of inflammatory cell chemotaxis activity in vitro.
In conclusion, in this study, we demonstrated that C3aR/C5aR deficiency resulted in reduced proteinuria and attenuated histological injury in an IgAN mouse model. This protective effect may be attributed partly to inhibition of the renal expression of cytokines and chemokines. We also validated that blocking C3aR or C5aR can inhibit cytokine and chemokine secretion and cell proliferation in cultured HMCs. Our data have provided us with profound evidence indicating that blocking C3aR or C5aR may be a promising therapy for patients with IgAN.
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